Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Palivizumab biosimilar by Mabxience Holding for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Palivizumab biosimilar is under clinical development by Mabxience Holding and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections....